OCGN Quote, Financials, Valuation and Earnings

Insmed has a net margin of -1141.73% compared to Ocugen's net margin of -236.04%. Ocugen's return on equity of -136.91% beat Insmed's return on equity of --.

Ocugen has a consensus price target of --, signalling upside risk potential of 639.12%. On the other hand Insmed has an analysts' consensus of $88.25 which suggests that it could grow by 26.78%. Given that Ocugen has higher upside potential than Insmed, analysts believe Ocugen is more attractive than Insmed.

Ocugen has a beta of 3.823, which suggesting that the stock is 282.261% more volatile than S&P 500. In comparison Insmed has a beta of 1.103, suggesting its more volatile than the S&P 500 by 10.328%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $1.1M, which are smaller than Insmed quarterly revenues of $93.4M. Ocugen's net income of -$13M is higher than Insmed's net income of -$220.5M. Notably, Ocugen's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 47.20x versus 31.55x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Mirum Pharmaceuticals has a net margin of -1141.73% compared to Ocugen's net margin of -15.75%. Ocugen's return on equity of -136.91% beat Mirum Pharmaceuticals's return on equity of -41.13%.

Ocugen has a consensus price target of --, signalling upside risk potential of 639.12%. On the other hand Mirum Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 51.59%. Given that Ocugen has higher upside potential than Mirum Pharmaceuticals, analysts believe Ocugen is more attractive than Mirum Pharmaceuticals.

Ocugen has a beta of 3.823, which suggesting that the stock is 282.261% more volatile than S&P 500. In comparison Mirum Pharmaceuticals has a beta of 1.200, suggesting its more volatile than the S&P 500 by 19.974%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Mirum Pharmaceuticals pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $1.1M, which are smaller than Mirum Pharmaceuticals quarterly revenues of $90.4M. Ocugen's net income of -$13M is higher than Mirum Pharmaceuticals's net income of -$14.2M. Notably, Ocugen's price-to-earnings ratio is -- while Mirum Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 47.20x versus 6.38x for Mirum Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

MetaVia has a net margin of -1141.73% compared to Ocugen's net margin of --. Ocugen's return on equity of -136.91% beat MetaVia's return on equity of --.

Ocugen has a consensus price target of --, signalling upside risk potential of 639.12%. On the other hand MetaVia has an analysts' consensus of -- which suggests that it could grow by 884.85%. Given that MetaVia has higher upside potential than Ocugen, analysts believe MetaVia is more attractive than Ocugen.

Ocugen has a beta of 3.823, which suggesting that the stock is 282.261% more volatile than S&P 500. In comparison MetaVia has a beta of -0.250, suggesting its less volatile than the S&P 500 by 125.025%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. MetaVia pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $1.1M, which are larger than MetaVia quarterly revenues of --. Ocugen's net income of -$13M is lower than MetaVia's net income of -$5.7M. Notably, Ocugen's price-to-earnings ratio is -- while MetaVia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 47.20x versus -- for MetaVia. Usually stocks with elevated PS ratios are considered overvalued.

Scholar Rock Holding has a net margin of -1141.73% compared to Ocugen's net margin of --. Ocugen's return on equity of -136.91% beat Scholar Rock Holding's return on equity of --.

Ocugen has a consensus price target of --, signalling upside risk potential of 639.12%. On the other hand Scholar Rock Holding has an analysts' consensus of $46.38 which suggests that it could grow by 4.31%. Given that Ocugen has higher upside potential than Scholar Rock Holding, analysts believe Ocugen is more attractive than Scholar Rock Holding.

Ocugen has a beta of 3.823, which suggesting that the stock is 282.261% more volatile than S&P 500. In comparison Scholar Rock Holding has a beta of 0.578, suggesting its less volatile than the S&P 500 by 42.249%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Scholar Rock Holding pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $1.1M, which are larger than Scholar Rock Holding quarterly revenues of --. Ocugen's net income of -$13M is higher than Scholar Rock Holding's net income of -$64.5M. Notably, Ocugen's price-to-earnings ratio is -- while Scholar Rock Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 47.20x versus 89.95x for Scholar Rock Holding. Usually stocks with elevated PS ratios are considered overvalued.